Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obiltoxaximab, an antibody targeting Anthrax protective antigen.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Frexalimab, an antibody targeting CD40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Belimumab, an antibody targeting BAFF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anifrolumab, an antibody targeting IFNAR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clazakizumab, an antibody targeting IL-6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Siltuximab, an antibody targeting IL-6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sarilumab, an antibody targeting IL-6R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tocilizumab, an antibody targeting IL-6R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Astegolimab, an antibody targeting ST2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Itepekimab, an antibody targeting IL-33.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Depemokimab, an antibody targeting IL-5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Benralizumab, an antibody targeting IL-5RA.